Gangxiong Huang, MD
Tcelltech Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gangxiong Huang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07485504 · Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic MalignanciesTcelltech Inc. · not yet recruiting · Relapsed or Refractory Hematologic Malignancies · study chair
- Ph1NCT07231081 · Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid TumorsTcelltech Inc. · suspended · Solid Tumors · study chair
- Ph1NCT07052383 · Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc. · suspended · Osteosarcoma, Soft Tissue Sarcoma · study chair
- Ph1NCT06482905 · Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.Tcelltech Inc. · recruiting · High-grade Glioma, WHO Grade Ⅳ Glioma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in osteosarcoma.